Qingfeng Yu

Qingfeng Yu

Auto-generated profile, based on publicly available information

Qingfeng Yu

Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
QYQingfeng Yu
Qingfeng Yu
CWChengjie Wu
Chengjie Wu
YCYeda Chen
Yeda Chen
BLBingsheng Li
Bingsheng Li
RWRuixiao Wang
Ruixiao Wang
GZGuohua Zeng
Guohua Zeng
Overactive bladder (OAB) is the most bothersome symptom in lower urinary tract symptoms (LUTS). Current pharmacologic treatment aims to inhibit detrusor contraction; however, shows unsatisfied efficacy and high discontinuation rate. LIM kinases (LIMKs) promote smooth muscle contraction in the prostate; however, their function in the bladder smooth muscle remains unclear. Here, we studied effects of the LIMK inhibitors on bladder smooth muscle contraction and proliferation both in vitro and in vivo experiments. Bladder expressions of LIMKs are elevated in OAB rat detrusor tissues. Two LIMK inhibitors, SR7826 and LIMKi3, inhibit contraction of human detrusor strip, and cause actin filament breakdown, as well as cell proliferation reduction in cultured human bladder smooth muscle cells (HBSMCs), paralleled by reduced cofilin phosphorylation. Silencing of LIMK1 and LIMK2 in HBSMCs resulted in breakdown of actin filaments and decreased cell proliferation. Treatment with SR7826 or LIMKi3 decreased micturition frequency and bladder detrusor hypertrophy in rats with bladder outlet obstruction. Our study suggests that LIMKs may promote contraction and proliferation in the bladder smooth muscle, which could be inhibited by small molecule LIMK inhibitors. LIMK inhibitors could be a potential therapeutic strategy for OAB- related LUTS.

7 April 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BLBingsheng Li
Bingsheng Li
QYQingfeng Yu
Qingfeng Yu
RWRuixiao Wang
Ruixiao Wang
CGChristian Gratzke
Christian Gratzke
XIAOLONG WANGXIAOLONG WANG
XIAOLONG WANG
MHMartin Hennenberg
Martin Hennenberg
Introduction: Lower urinary tract symptoms (LUTS) due to overactive bladder (OAB) are caused by spontaneous detrusor contractions. Medical treatment with muscarinic receptor antagonists or β3-adrenoceptor agonists aims to inhibit detrusor contractions, but overall results are unsatisfactory. Consequently, improved understanding of bladder smooth muscle contraction and identification of novel compounds for its inhibition are needed to develop alternative options. A role of the GTPase Rac1 for smooth muscle contraction has been reported from the prostate, but is unknown in the human detrusor. Here, we examined effects of the Rac inhibitors NSC23766, which may also antagonize muscarinic receptors, and EHT1864 on contraction of human detrusor tissues. Methods: Female and male human detrusor tissues were obtained from radical cystectomy. Effects of NSC23766 (100 µM) and EHT1864 (100 µM) on detrusor contractions were studied in an organ bath. Results: Electric field stimulation induced frequency-dependent contractions of detrusor tissues, which were inhibited by NSC23766 and EHT1864. Carbachol induced concentration-dependent contractions. Concentration response curves for carbachol were shifted to the right by NSC23766, reflected by increased EC50 values, but unchanged Emax values. EHT1864 reduced carbachol-induced contractions, resulting in reduced Emax values for carbachol. The thromboxane analog U46619 induced concentration-dependent contractions, which remained unchanged by NSC23766, but were reduced by EHT1864. Conclusions: NSC23766 and EHT1864 inhibit female and male human detrusor contractions. NSC23766, but not EHT1864 competitively antagonizes muscarinic receptors. In addition to neurogenic and cholinergic contractions, EHT1864 inhibits thromboxane A2-induced detrusor contractions. The latter may be promising, as the origin of spontaneous detrusor contractions in OAB is noncholinergic. In vivo, both compounds may improve OAB-related LUTS.

5 March 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MLMing Lei
Ming Lei
HLHongyu Lan
Hongyu Lan
DGDi Gu
Di Gu
MCMing Chen
Ming Chen
XQXin Qiu
Xin Qiu
QYQingfeng Yu
Qingfeng Yu

24 March 2017 in European Urology Supplements
Verified
Journal Article
Closed access
MHMartin Hennenberg
Martin Hennenberg
YWY. Wang
Y. Wang
AHA. Herlemann
A. Herlemann
QYQ. Yu
Q. Yu
FSF. Strittmatter
F. Strittmatter
CGC. Gratzke
C. Gratzke


24 March 2017 in European Urology Supplements
Verified
Journal Article
Closed access
YWY. Wang
Y. Wang
CGC. Gratzke
C. Gratzke
BRB. Rutz
B. Rutz
QYQ. Yu
Q. Yu
FSF. Strittmatter
F. Strittmatter
MHMartin Hennenberg
Martin Hennenberg